Repligen
RGEN
#2039
Rank
ยฃ6.99 B
Marketcap
ยฃ124.34
Share price
-0.46%
Change (1 day)
5.93%
Change (1 year)
Categories

Repligen (RGEN) - Total debt

Total debt on the balance sheet as of September 2025 : ยฃ0.51 Billion

According to Repligen 's latest financial reports the company's total debt is ยฃ0.51 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Repligen - Total debt on balance sheet (from 2004 to 2025)

Total debt by year

Year Total debt Change
2024-12-31ยฃ0.54 B-2.12%
2023-12-31ยฃ0.55 B59.81%
2022-12-31ยฃ0.34 B28.92%
2021-12-31ยฃ0.27 B34.21%
2020-12-31ยฃ0.20 B0.62%
2019-12-31ยฃ0.20 B146.3%
2018-12-31ยฃ81.52 M11.02%
2017-12-31ยฃ73.43 M-4.89%
2016-12-31ยฃ77.21 M
2005-03-31ยฃ0.06 M37.95%
2004-03-31ยฃ0.04 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
Novavax
NVAX
ยฃ0.18 B-63.54%๐Ÿ‡บ๐Ÿ‡ธ USA
BioMarin Pharmaceutical
BMRN
ยฃ0.45 B-12.28%๐Ÿ‡บ๐Ÿ‡ธ USA
Neurocrine Biosciences
NBIX
ยฃ0.32 B-37.81%๐Ÿ‡บ๐Ÿ‡ธ USA
General Electric
GE
ยฃ15.63 B 2,924.97%๐Ÿ‡บ๐Ÿ‡ธ USA
Thermo Fisher Scientific
TMO
ยฃ26.76 B 5,079.52%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
ยฃ38.28 B 7,309.41%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
ยฃ45.64 B 8,733.05%๐Ÿ‡บ๐Ÿ‡ธ USA
Bio-Techne
TECH
ยฃ0.29 B-42.74%๐Ÿ‡บ๐Ÿ‡ธ USA
Sangamo Therapeutics
SGMO
ยฃ19.07 M-96.31%๐Ÿ‡บ๐Ÿ‡ธ USA
Charles River Laboratories
CRL
ยฃ1.97 B 281.59%๐Ÿ‡บ๐Ÿ‡ธ USA